Related Experiment Video
Updated: Jun 21, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Drugs mediating myocardial protection.
Stefan G De Hert1, Benedikt Preckel, Markus W Hollmann
1Department of Anaesthesiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. s.g.dehert@amc.uva.nl
Myocardial ischemia can cause dysfunction, and reperfusion injury can impair heart function even after successful revascularization. This review focuses on pharmacological strategies to prevent and treat myocardial reperfusion injury.
Area of Science:
- Cardiology
- Cardiovascular Research
- Pharmacology
Background:
- Myocardial ischemia leads to reversible or irreversible myocardial dysfunction.
- Reperfusion injury can transiently impair cardiac function post-revascularization.
- Effective treatment requires restoring blood flow and mitigating reperfusion injury.
Purpose of the Study:
- To review strategies for managing myocardial reperfusion injury.
- To focus on pharmacological treatments for myocardial reperfusion injury.
Main Methods:
- Literature review of pharmacological interventions.
- Analysis of strategies to prevent and alleviate reperfusion injury.
Main Results:
- Various pharmacological strategies have been developed to address myocardial reperfusion injury.
- These treatments aim to minimize damage caused by restoring blood flow.
Conclusions:
- Pharmacological interventions are crucial for managing myocardial reperfusion injury.
- Further research into these strategies can improve patient outcomes after ischemic events.
More Related Videos
09:53Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure Drugs: Inotropic Agents
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: β-Blockers
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...